Verona Pharma plc
VRNA
Peringkat dalam Saham
#2233
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Harga Saham
$106.91
Terakhir disinkronkan: 2025-10-07
Kapitalisasi Pasar
$9.09B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Verona Pharma plc (VRNA)
Kategori
Healthcare
Laba untuk Verona Pharma plc (VRNA)
Laba pada Jun 2025 TTM: $-56.52M
Menurut laporan keuangan terbaru dari Verona Pharma plc, laba saat ini perusahaan adalah $-56.52M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-42.28M, peningkatan dibandingkan laba tahun 2022 sebesar $-56.62M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Verona Pharma plc dari 2005 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-56.52M | -56.62% |
| 2024 | $-130.30M | 208.20% |
| 2023 | $-42.28M | -25.33% |
| 2022 | $-56.62M | 37.75% |
| 2021 | $-41.10M | -13.52% |
| 2020 | $-47.53M | 17.27% |
| 2019 | $-40.53M | 31.86% |
| 2018 | $-30.74M | -9.75% |
| 2017 | $-34.06M | 362.02% |
| 2016 | $-7.37M | -44.44% |
| 2015 | $-13.27M | 126.33% |
| 2014 | $-5.86M | 25.78% |
| 2013 | $-4.66M | 75.08% |
| 2012 | $-2.66M | -40.09% |
| 2011 | $-4.44M | -2.04% |
| 2010 | $-4.54M | 8.38% |
| 2009 | $-4.18M | 45.74% |
| 2008 | $-2.87M | -40.29% |
| 2007 | $-4.81M | 105.89% |
| 2006 | $-2.34M | -3,133.92% |
| 2005 | $76.99K | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -9,432.91% |
US
|
|
| $-3.09B | 5,361.85% |
US
|
|
| $-4.02B | 7,005.88% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,551.30% |
NL
|
